Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple-negative Breast Cancer|Nab-paclitaxel
Interventions: DRUG: Nab-paclitaxel + Carboplatin|DRUG: Nab-paclitaxel + Epirubicin
Sponsor: Hebei Medical University Fourth Hospital
Collaborators: Beijing 302 Hospital|CSPC Ouyi Pharmaceutical Co., Ltd.